Overview
- Plaintiffs filed a federal securities class action accusing Medpace Holdings of concealing high backlog cancellation rates and repeatedly overstating its fourth‑quarter 2025 book‑to‑bill projections.
- The complaint says Medpace reported a book‑to‑bill ratio of 1.04 on February 9, 2026, a figure below prior guidance that the suit says caused the company’s stock to drop sharply.
- Several plaintiff law firms have issued investor notices and are soliciting clients to move for lead‑plaintiff appointment before early‑June deadlines, commonly June 5–8, 2026.
- The case, captioned Durbin v. Medpace in the U.S. District Court for the Southern District of Ohio, awaits the court’s decision on which investor group will lead and pick counsel.
- If a lead plaintiff is appointed, that party could steer the litigation into document discovery, seek testimony from executives, and shape any shareholder recovery while investors remain unrepresented until a class is certified.